Hemovent expands Series A
Hemovent said today it received an undisclosed amount of funding as part of an oversubscribed Series A expansion round. The funds came from all existing investors, the Aachen, Germany-based company said, as well as newly invested 1st Capital Partner. Hemovent said that the funding comes shortly after it completed the 1st series of in vivo trials of its artificial lung technology platform which it is developing for a range of indications including extracorporeal CO2 removal and extracorporeal life support. “The fact that all Hemovent investors participated in this new round, and that 1st Capital Partner is an experienced life sciences investment firm known for investing sizable funds in both early-stage and follow-on rounds, bears strong testimony to the opportunity ahead of us as well as the efficient progress we have been able to make to date. Our investors understand Hemovent’s platform is positioned to disrupt a billion-dollar market. In vivo trials have already validated our platform’s superior blood-handling behavior and efficiency parameters compared to standard ECMO. We expect when Hemovent is available by mid-next year it will immediately drive ECMO usage not only for ECLS but also as an effective therapy for respiratory failure indications including ECCO2R protocols,” CEO Christof Lenz said in a prepared statement. Last February, Hemovent said it raised $6m in a Series A round to support its portable extra corporeal membrane oxygenat...
Conclusion: IT following lung and liver transplantation, with injection of islets into a transplanted organ, is feasible. It improves C-peptide secretion, decreases insulin needs, and lowers HbA1c.Horm Res Paediatr
Organs donated from people infected with hepatitis C can be safely transplanted, and any transmission of the virus can be treated with antiretrovirals, new research shows.Medscape Medical News
Conditions: Idiopathic Pulmonary Fibrosis; Emphysema or COPD Interventions: Biological: CD3/CD19 negative hematopoietic stem cells; Drug: Rituximab; Drug: Alemtuzumab; Drug: Fludarabine; Drug: Thiotepa; Drug: G-CSF; Drug: Hydroxyurea Sponsor: Paul Szabolcs Not yet recruiting
Condition: Lung Transplant Rejection Intervention: Device: photopheresis Sponsors: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Italian Cystic Fibrosis Research Foundation Not yet recruiting
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
In his book, The Checklist Manifesto: How to Get Things Right, Atul Gawande describes the origins of the checklist that involved the airline industry beginnings of the B-17 airplane.1 The test plane ’s flight ended in a deadly crash deemed due to pilot error. The B-17 was felt to be too much plane for one pilot and was abandoned as the next generation long-range bomber for the U.S. military. A persistent group of pilots developed a checklist of tasks to be performed for each phase of flight t ake-off, inflight, and landing.
Transplant International,Volume 31, Issue 5, Page 481-483, May 2018.